Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/06/068878
CTRI/2024/06/068878
Not yet recruiting
Phase 4

Efficacy And Safety Of Add On Aprepitant to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea & vomiting in locally advanced head & neck squamous cell carcinoma : A Randomized, Double Blind, Controlled Clinical Trial - NI

Pt BD Sharma UHS Rohtak0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Pt BD Sharma UHS Rohtak
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Pt BD Sharma UHS Rohtak

Eligibility Criteria

Inclusion Criteria

  • •Histologically confirmed cases of squamous cell carcinoma in head \& neck region with any stage between Stages III\-IV B.
  • •Patients with ECOG performance status 0–1
  • •Patients with adequate organ and bone marrow function.
  • •Patient is able to swallow tablets

Exclusion Criteria

  • •advanced stage malignancies(above Stage IVB)
  • •History of nausea and emesis occurred 24h before the start of CCRT.
  • •Conditions like severe cardiovascular, pulmonary, diabetic, mental, and other diseases.
  • •Pregnant or lactating females.
  • •Drug h/o corticosteroid or benzodiazepines.
  • •History of Drug/Alcohol addictions.
  • •N\&V provoking conditions like brain metastasis, gastrointestinal obstruction, hypocalcemia;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Evaluation of the efficacy of Aprepitant in vomiting of children with cancerMalignant cancer.Agranulocytosis secondary to cancer chemotherapyD70.1
IRCT20200204046377N1Shahid Beheshti University of Medical Sciences30
Recruiting
Phase 2
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.
IRCT20090613002027N21Mazandaran University of Medical Sciences60
Completed
Not Applicable
Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapyType 2 diabetes
JPRN-UMIN000010849Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine40
Not yet recruiting
Phase 2
Evaluation of effective and safe use of a new drug Apremilast [a Phosphodiesterase enzyme inhibitor (PDE-4 inhibitor)] in patients suffering from unstable white patch-a skin condition called vitiligo.Health Condition 1: L80- Vitiligo
CTRI/2019/07/020234AIIMS JODHPUR
Completed
Not Applicable
Evaluation of combinational effect of Aprepitant and Dxamethasone on nausea and vomiting induced by high-emetic-risk chemotherapy in patients.
JPRN-UMIN000010818Osaka Medical College Hospital200